Skip to main content

Table 4 Risk factor for all-cause mortality up to 60 days following allogeneic hematopoietic stem cell transplantation

From: Breakthrough viridans streptococcal bacteremia in allogeneic hematopoietic stem cell transplant recipients receiving levofloxacin prophylaxis in a Japanese hospital

Univariate analysis

 Pre-transplant factors

Variables (Number)

Mortality (%)

P-value

  Gender

Male (119)

19.3

0.13

Female (65)

10.8

 

  Age

≥60 (80)

18.8

0.42

<60 (104)

14.4

 

  Diagnosis

Myeloid malignacy (119)

16.8

0.83

non Myeloid malignancy (65)

15.4

 

  Diseases risk

High risk hematological diseases (151)

19.2

0.028

Standard risk hematological diseases (33)

3.03

 

  PH of allo-HSCT

Yes (25)

32.0

0.017

No (159)

13.8

 

  Donor typre

CBT (135)

19.3

0.076

non CBT (49)

8.16

 

  Conditioning

RIC(63)

22.3

0.11

MAC (121)

13.2

 

 Time dependent factors

   

  Viridans streptococcal bacteremia

VSB (28)

10.7

0.43

non VSB (156)

17.3

 

  Engraftment within Day30

Yes (161)

9.94

<0.001

No (23)

60.9

 

Multivariate analysis

   

 Factors

Hazard ratio

95 % confidence interval

P-value

  High risk hematological diseases

5.59

0.741–42.18

0.095

  Prior history of allo-HSCT

2.09

0.919–4.740

0.079

  CBT

1.66

0.569–4.839

0.35

  Engraftment within Day30

0.22

0.087–0.558

0.0014

  1. CBT cord blood transplantation, RIC reduced-intensity conditioning, MAC Myeloablative conditioning, allo-HSCT allogeneic hematopoietic stem cell transplantation, VSB viridans streptococcal bacteremia, PH-allo-HSCT prior history of allogeneic hematopoietic stem cell transplantation